In recent years, molecular targeted therapy has significantly improved in non-small cell lung cancer, offering enhanced alternatives for clinical diagnosis and treatment, particularly for advanced lung adenocarcinoma and other lung cancer variants with adenocarcinoma components, EGFR tyrosine kinase inhibitors (EGFR-TKIs) have emerged as the primary pharmacological agents for the management of intermediate and advanced non-small cell lung cancer, these novel targeted medicines not only markedly enhanced clinical results but also prolonged patient survival (9, 11, 12). Here, EGFR is linked to lung cancer.